APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Alpha-1 Lung Disease

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Alpha-1 Lung Disease Market Outlook and Growth Opportunities 2026

Report ID 17396221042 January 2026205 pages

Choose your research edition.

Industry ResearchAlpha-1 Lung Disease Industry Research Report 2026142 pages · $2,950 USDIndustry Growth & TrendsGlobal Alpha-1 Lung Disease Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Alpha-1 Lung Disease Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Alpha-1 Lung Disease Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal Alpha-1 Lung Disease Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

The global Alpha-1 Lung Disease market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Alpha-1 Lung Disease is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Alpha-1 Lung Disease is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Alpha-1 Lung Disease is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Alpha-1 Lung Disease market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Alpha-1 Lung Disease market include Takeda, Pfizer, GlaxoSmithKline, Baxter, AstraZeneca, Vertex Pharmaceuticals, Teva Pharmaceutical Industries, ProMetic Life Sciences and ProBioGen, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Alpha-1 Lung Disease market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Alpha-1 Lung Disease and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Alpha-1 Lung Disease revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Alpha-1 Lung Disease market.

Alpha-1 Lung Disease Segment by Company

Takeda

Pfizer

GlaxoSmithKline

Baxter

AstraZeneca

Vertex Pharmaceuticals

Teva Pharmaceutical Industries

ProMetic Life Sciences

ProBioGen

LFB Biomedicaments

Kedrion Group

Kamada Ltd

Grifols

CSL Behring

Chiesi Pharmaceuticals

Boehringer Ingelheim

Biogen

Baxalta

Arrowhead Research Corporation

Abeona Therapeutics

Alpha-1 Lung Disease Segment by Type

Non-CF Bronchiectasis(NCFB)

Cystic Fibrosis(CF)

Augmentation Therapy

Other

Alpha-1 Lung Disease Segment by Application

Pharmacies

Hospitals

Specialty Clinics

Others

Alpha-1 Lung Disease Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Alpha-1 Lung Disease status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Alpha-1 Lung Disease key companies, revenue, market share, and recent developments.

3. To split the Alpha-1 Lung Disease breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Alpha-1 Lung Disease market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Alpha-1 Lung Disease significant trends, drivers, influence factors in global and regions.

6. To analyze Alpha-1 Lung Disease competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Alpha-1 Lung Disease market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Alpha-1 Lung Disease and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Alpha-1 Lung Disease.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Alpha-1 Lung Disease industry.

Chapter 3: Detailed analysis of Alpha-1 Lung Disease company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Alpha-1 Lung Disease in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Alpha-1 Lung Disease in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Alpha-1 Lung Disease Industry Trends Table 2. Alpha-1 Lung Disease Industry Drivers Table 3. Alpha-1 Lung Disease Industry Opportunities and Challenges Table 4. Alpha-1 Lung Disease Industry Restraints Table 5. Global Alpha-1 Lung Disease Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Alpha-1 Lung Disease Revenue Share by Company (2021-2026) Table 7. Global Alpha-1 Lung Disease Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Alpha-1 Lung Disease Key Company Manufacturing Base & Headquarters Table 9. Global Alpha-1 Lung Disease Company, Product Type & Application Table 10. Global Alpha-1 Lung Disease Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Alpha-1 Lung Disease by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Non-CF Bronchiectasis(NCFB) Table 15. Significant Companies of Cystic Fibrosis(CF) Table 16. Significant Companies of Augmentation Therapy Table 17. Significant Companies of Other Table 18. Global Alpha-1 Lung Disease Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Alpha-1 Lung Disease Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Alpha-1 Lung Disease Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Alpha-1 Lung Disease Sales Value Share by Type (2021-2026) Table 22. Global Alpha-1 Lung Disease Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Pharmacies Table 24. Significant Companies of Hospitals Table 25. Significant Companies of Specialty Clinics Table 26. Significant Companies of Others Table 27. Global Alpha-1 Lung Disease Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Alpha-1 Lung Disease Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Alpha-1 Lung Disease Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Alpha-1 Lung Disease Sales Value Share by Application (2021-2026) Table 31. Global Alpha-1 Lung Disease Sales Value Share by Application (2027-2032) Table 32. Global Alpha-1 Lung Disease Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Alpha-1 Lung Disease Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Alpha-1 Lung Disease Sales Value Share by Region (2021-2026) Table 35. Global Alpha-1 Lung Disease Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Alpha-1 Lung Disease Sales Value Share by Region (2027-2032) Table 37. Global Alpha-1 Lung Disease Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Alpha-1 Lung Disease Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Alpha-1 Lung Disease Sales Value Market Share by Country (2021-2026) Table 40. Global Alpha-1 Lung Disease Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Alpha-1 Lung Disease Sales Value Market Share by Country (2027-2032) Table 42. Takeda Company Information Table 43. Takeda Business Overview Table 44. Takeda Alpha-1 Lung Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Takeda Alpha-1 Lung Disease Product Portfolio Table 46. Takeda Recent Development Table 47. Pfizer Company Information Table 48. Pfizer Business Overview Table 49. Pfizer Alpha-1 Lung Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Pfizer Alpha-1 Lung Disease Product Portfolio Table 51. Pfizer Recent Development Table 52. GlaxoSmithKline Company Information Table 53. GlaxoSmithKline Business Overview Table 54. GlaxoSmithKline Alpha-1 Lung Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. GlaxoSmithKline Alpha-1 Lung Disease Product Portfolio Table 56. GlaxoSmithKline Recent Development Table 57. Baxter Company Information Table 58. Baxter Business Overview Table 59. Baxter Alpha-1 Lung Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Baxter Alpha-1 Lung Disease Product Portfolio Table 61. Baxter Recent Development Table 62. AstraZeneca Company Information Table 63. AstraZeneca Business Overview Table 64. AstraZeneca Alpha-1 Lung Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. AstraZeneca Alpha-1 Lung Disease Product Portfolio Table 66. AstraZeneca Recent Development Table 67. Vertex Pharmaceuticals Company Information Table 68. Vertex Pharmaceuticals Business Overview Table 69. Vertex Pharmaceuticals Alpha-1 Lung Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Vertex Pharmaceuticals Alpha-1 Lung Disease Product Portfolio Table 71. Vertex Pharmaceuticals Recent Development Table 72. Teva Pharmaceutical Industries Company Information Table 73. Teva Pharmaceutical Industries Business Overview Table 74. Teva Pharmaceutical Industries Alpha-1 Lung Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Teva Pharmaceutical Industries Alpha-1 Lung Disease Product Portfolio Table 76. Teva Pharmaceutical Industries Recent Development Table 77. ProMetic Life Sciences Company Information Table 78. ProMetic Life Sciences Business Overview Table 79. ProMetic Life Sciences Alpha-1 Lung Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. ProMetic Life Sciences Alpha-1 Lung Disease Product Portfolio Table 81. ProMetic Life Sciences Recent Development Table 82. ProBioGen Company Information Table 83. ProBioGen Business Overview Table 84. ProBioGen Alpha-1 Lung Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. ProBioGen Alpha-1 Lung Disease Product Portfolio Table 86. ProBioGen Recent Development Table 87. LFB Biomedicaments Company Information Table 88. LFB Biomedicaments Business Overview Table 89. LFB Biomedicaments Alpha-1 Lung Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. LFB Biomedicaments Alpha-1 Lung Disease Product Portfolio Table 91. LFB Biomedicaments Recent Development Table 92. Kedrion Group Company Information Table 93. Kedrion Group Business Overview Table 94. Kedrion Group Alpha-1 Lung Disease Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Kedrion Group Alpha-1 Lung Disease Product Portfolio Table 96. Kedrion Group Recent Development Table 97. Kamada Ltd Company Information Table 98. Kamada Ltd Business Overview Table 99. Kamada Ltd Alpha-1 Lung Disease Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Kamada Ltd Alpha-1 Lung Disease Product Portfolio Table 101. Kamada Ltd Recent Development Table 102. Grifols Company Information Table 103. Grifols Business Overview Table 104. Grifols Alpha-1 Lung Disease Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Grifols Alpha-1 Lung Disease Product Portfolio Table 106. Grifols Recent Development Table 107. CSL Behring Company Information Table 108. CSL Behring Business Overview Table 109. CSL Behring Alpha-1 Lung Disease Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. CSL Behring Alpha-1 Lung Disease Product Portfolio Table 111. CSL Behring Recent Development Table 112. Chiesi Pharmaceuticals Company Information Table 113. Chiesi Pharmaceuticals Business Overview Table 114. Chiesi Pharmaceuticals Alpha-1 Lung Disease Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Chiesi Pharmaceuticals Alpha-1 Lung Disease Product Portfolio Table 116. Chiesi Pharmaceuticals Recent Development Table 117. Boehringer Ingelheim Company Information Table 118. Boehringer Ingelheim Business Overview Table 119. Boehringer Ingelheim Alpha-1 Lung Disease Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Boehringer Ingelheim Alpha-1 Lung Disease Product Portfolio Table 121. Boehringer Ingelheim Recent Development Table 122. Biogen Company Information Table 123. Biogen Business Overview Table 124. Biogen Alpha-1 Lung Disease Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Biogen Alpha-1 Lung Disease Product Portfolio Table 126. Biogen Recent Development Table 127. Baxalta Company Information Table 128. Baxalta Business Overview Table 129. Baxalta Alpha-1 Lung Disease Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Baxalta Alpha-1 Lung Disease Product Portfolio Table 131. Baxalta Recent Development Table 132. Arrowhead Research Corporation Company Information Table 133. Arrowhead Research Corporation Business Overview Table 134. Arrowhead Research Corporation Alpha-1 Lung Disease Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Arrowhead Research Corporation Alpha-1 Lung Disease Product Portfolio Table 136. Arrowhead Research Corporation Recent Development Table 137. Abeona Therapeutics Company Information Table 138. Abeona Therapeutics Business Overview Table 139. Abeona Therapeutics Alpha-1 Lung Disease Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. Abeona Therapeutics Alpha-1 Lung Disease Product Portfolio Table 141. Abeona Therapeutics Recent Development Table 142. Research Programs/Design for This Report Table 143. Authors List of This Report Table 144. Secondary Sources Table 145. Primary Sources List of Figures Figure 1. Alpha-1 Lung Disease Product Image Figure 2. Global Alpha-1 Lung Disease Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Alpha-1 Lung Disease Market Size (2021-2032) & (US$ Million) Figure 4. Global Alpha-1 Lung Disease Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Non-CF Bronchiectasis(NCFB) Image Figure 8. Cystic Fibrosis(CF) Image Figure 9. Augmentation Therapy Image Figure 10. Other Image Figure 11. Global Alpha-1 Lung Disease Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Alpha-1 Lung Disease Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Alpha-1 Lung Disease Sales Value Share by Type (2021-2032) Figure 14. Pharmacies Image Figure 15. Hospitals Image Figure 16. Specialty Clinics Image Figure 17. Others Image Figure 18. Global Alpha-1 Lung Disease Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Alpha-1 Lung Disease Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Alpha-1 Lung Disease Sales Value Share by Application (2021-2032) Figure 21. Global Alpha-1 Lung Disease Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Alpha-1 Lung Disease Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Alpha-1 Lung Disease Sales Value (2021-2032) & (US$ Million) Figure 24. North America Alpha-1 Lung Disease Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Alpha-1 Lung Disease Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Alpha-1 Lung Disease Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Alpha-1 Lung Disease Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Alpha-1 Lung Disease Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Alpha-1 Lung Disease Sales Value (2021-2032) & (US$ Million) Figure 30. South America Alpha-1 Lung Disease Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Alpha-1 Lung Disease Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Alpha-1 Lung Disease Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Non-CF Bronchiectasis(NCFB)
  • Cystic Fibrosis(CF)
  • Augmentation Therapy
  • Other
Applications
  • Pharmacies
  • Hospitals
  • Specialty Clinics
  • Others
Companies covered
  • Takeda
  • Pfizer
  • GlaxoSmithKline
  • Baxter
  • AstraZeneca
  • Vertex Pharmaceuticals
  • Teva Pharmaceutical Industries
  • ProMetic Life Sciences
  • ProBioGen
  • LFB Biomedicaments
  • Kedrion Group
  • Kamada Ltd
  • Grifols
  • CSL Behring
  • Chiesi Pharmaceuticals
  • Boehringer Ingelheim
  • Biogen
  • Baxalta
  • Arrowhead Research Corporation
  • Abeona Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Alpha-1 Lung Disease Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Alpha-1 Lung Disease Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Alpha-1 Lung Disease Market Dynamics
  1. 2.1 Alpha-1 Lung Disease Industry Trends
  2. 2.2 Alpha-1 Lung Disease Industry Drivers
  3. 2.3 Alpha-1 Lung Disease Industry Opportunities and Challenges
  4. 2.4 Alpha-1 Lung Disease Industry Restraints
3 Alpha-1 Lung Disease Market by Company
  1. 3.1 Global Alpha-1 Lung Disease Company Revenue Ranking in 2025
  2. 3.2 Global Alpha-1 Lung Disease Revenue by Company (2021-2026)
  3. 3.3 Global Alpha-1 Lung Disease Company Ranking (2024-2026)
  4. 3.4 Global Alpha-1 Lung Disease Company Manufacturing Base and Headquarters
  5. 3.5 Global Alpha-1 Lung Disease Company Product Type and Application
  6. 3.6 Global Alpha-1 Lung Disease Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Alpha-1 Lung Disease Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Alpha-1 Lung Disease Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Alpha-1 Lung Disease Market by Type
  1. 4.1 Alpha-1 Lung Disease Type Introduction
  2. 4.1.1 Non-CF Bronchiectasis(NCFB)
  3. 4.1.2 Cystic Fibrosis(CF)
  4. 4.1.3 Augmentation Therapy
  5. 4.1.4 Other
  6. 4.2 Global Alpha-1 Lung Disease Sales Value by Type
  7. 4.2.1 Global Alpha-1 Lung Disease Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Alpha-1 Lung Disease Sales Value by Type (2021-2032)
  9. 4.2.3 Global Alpha-1 Lung Disease Sales Value Share by Type (2021-2032)
5 Alpha-1 Lung Disease Market by Application
  1. 5.1 Alpha-1 Lung Disease Application Introduction
  2. 5.1.1 Pharmacies
  3. 5.1.2 Hospitals
  4. 5.1.3 Specialty Clinics
  5. 5.1.4 Others
  6. 5.2 Global Alpha-1 Lung Disease Sales Value by Application
  7. 5.2.1 Global Alpha-1 Lung Disease Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Alpha-1 Lung Disease Sales Value by Application (2021-2032)
  9. 5.2.3 Global Alpha-1 Lung Disease Sales Value Share by Application (2021-2032)
6 Alpha-1 Lung Disease Regional Value Analysis
  1. 6.1 Global Alpha-1 Lung Disease Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Alpha-1 Lung Disease Sales Value by Region (2021-2032)
  3. 6.2.1 Global Alpha-1 Lung Disease Sales Value by Region: 2021-2026
  4. 6.2.2 Global Alpha-1 Lung Disease Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Alpha-1 Lung Disease Sales Value (2021-2032)
  7. 6.3.2 North America Alpha-1 Lung Disease Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Alpha-1 Lung Disease Sales Value (2021-2032)
  10. 6.4.2 Europe Alpha-1 Lung Disease Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Alpha-1 Lung Disease Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Alpha-1 Lung Disease Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Alpha-1 Lung Disease Sales Value (2021-2032)
  16. 6.6.2 South America Alpha-1 Lung Disease Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Alpha-1 Lung Disease Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Alpha-1 Lung Disease Sales Value Share by Country, 2025 VS 2032
7 Alpha-1 Lung Disease Country-level Value Analysis
  1. 7.1 Global Alpha-1 Lung Disease Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Alpha-1 Lung Disease Sales Value by Country (2021-2032)
  3. 7.2.1 Global Alpha-1 Lung Disease Sales Value by Country (2021-2026)
  4. 7.2.2 Global Alpha-1 Lung Disease Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Alpha-1 Lung Disease Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Alpha-1 Lung Disease Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Alpha-1 Lung Disease Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Alpha-1 Lung Disease Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Alpha-1 Lung Disease Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Pfizer
  8. 8.2.1 Pfizer Company Information
  9. 8.2.2 Pfizer Business Overview
  10. 8.2.3 Pfizer Alpha-1 Lung Disease Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer Alpha-1 Lung Disease Product Portfolio
  12. 8.2.5 Pfizer Recent Developments
  13. 8.3 GlaxoSmithKline
  14. 8.3.1 GlaxoSmithKline Company Information
  15. 8.3.2 GlaxoSmithKline Business Overview
  16. 8.3.3 GlaxoSmithKline Alpha-1 Lung Disease Revenue and Gross Margin (2021-2026)
  17. 8.3.4 GlaxoSmithKline Alpha-1 Lung Disease Product Portfolio
  18. 8.3.5 GlaxoSmithKline Recent Developments
  19. 8.4 Baxter
  20. 8.4.1 Baxter Company Information
  21. 8.4.2 Baxter Business Overview
  22. 8.4.3 Baxter Alpha-1 Lung Disease Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Baxter Alpha-1 Lung Disease Product Portfolio
  24. 8.4.5 Baxter Recent Developments
  25. 8.5 AstraZeneca
  26. 8.5.1 AstraZeneca Company Information
  27. 8.5.2 AstraZeneca Business Overview
  28. 8.5.3 AstraZeneca Alpha-1 Lung Disease Revenue and Gross Margin (2021-2026)
  29. 8.5.4 AstraZeneca Alpha-1 Lung Disease Product Portfolio
  30. 8.5.5 AstraZeneca Recent Developments
  31. 8.6 Vertex Pharmaceuticals
  32. 8.6.1 Vertex Pharmaceuticals Company Information
  33. 8.6.2 Vertex Pharmaceuticals Business Overview
  34. 8.6.3 Vertex Pharmaceuticals Alpha-1 Lung Disease Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Vertex Pharmaceuticals Alpha-1 Lung Disease Product Portfolio
  36. 8.6.5 Vertex Pharmaceuticals Recent Developments
  37. 8.7 Teva Pharmaceutical Industries
  38. 8.7.1 Teva Pharmaceutical Industries Company Information
  39. 8.7.2 Teva Pharmaceutical Industries Business Overview
  40. 8.7.3 Teva Pharmaceutical Industries Alpha-1 Lung Disease Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Teva Pharmaceutical Industries Alpha-1 Lung Disease Product Portfolio
  42. 8.7.5 Teva Pharmaceutical Industries Recent Developments
  43. 8.8 ProMetic Life Sciences
  44. 8.8.1 ProMetic Life Sciences Company Information
  45. 8.8.2 ProMetic Life Sciences Business Overview
  46. 8.8.3 ProMetic Life Sciences Alpha-1 Lung Disease Revenue and Gross Margin (2021-2026)
  47. 8.8.4 ProMetic Life Sciences Alpha-1 Lung Disease Product Portfolio
  48. 8.8.5 ProMetic Life Sciences Recent Developments
  49. 8.9 ProBioGen
  50. 8.9.1 ProBioGen Company Information
  51. 8.9.2 ProBioGen Business Overview
  52. 8.9.3 ProBioGen Alpha-1 Lung Disease Revenue and Gross Margin (2021-2026)
  53. 8.9.4 ProBioGen Alpha-1 Lung Disease Product Portfolio
  54. 8.9.5 ProBioGen Recent Developments
  55. 8.10 LFB Biomedicaments
  56. 8.10.1 LFB Biomedicaments Company Information
  57. 8.10.2 LFB Biomedicaments Business Overview
  58. 8.10.3 LFB Biomedicaments Alpha-1 Lung Disease Revenue and Gross Margin (2021-2026)
  59. 8.10.4 LFB Biomedicaments Alpha-1 Lung Disease Product Portfolio
  60. 8.10.5 LFB Biomedicaments Recent Developments
  61. 8.11 Kedrion Group
  62. 8.11.1 Kedrion Group Company Information
  63. 8.11.2 Kedrion Group Business Overview
  64. 8.11.3 Kedrion Group Alpha-1 Lung Disease Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Kedrion Group Alpha-1 Lung Disease Product Portfolio
  66. 8.11.5 Kedrion Group Recent Developments
  67. 8.12 Kamada Ltd
  68. 8.12.1 Kamada Ltd Company Information
  69. 8.12.2 Kamada Ltd Business Overview
  70. 8.12.3 Kamada Ltd Alpha-1 Lung Disease Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Kamada Ltd Alpha-1 Lung Disease Product Portfolio
  72. 8.12.5 Kamada Ltd Recent Developments
  73. 8.13 Grifols
  74. 8.13.1 Grifols Company Information
  75. 8.13.2 Grifols Business Overview
  76. 8.13.3 Grifols Alpha-1 Lung Disease Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Grifols Alpha-1 Lung Disease Product Portfolio
  78. 8.13.5 Grifols Recent Developments
  79. 8.14 CSL Behring
  80. 8.14.1 CSL Behring Company Information
  81. 8.14.2 CSL Behring Business Overview
  82. 8.14.3 CSL Behring Alpha-1 Lung Disease Revenue and Gross Margin (2021-2026)
  83. 8.14.4 CSL Behring Alpha-1 Lung Disease Product Portfolio
  84. 8.14.5 CSL Behring Recent Developments
  85. 8.15 Chiesi Pharmaceuticals
  86. 8.15.1 Chiesi Pharmaceuticals Company Information
  87. 8.15.2 Chiesi Pharmaceuticals Business Overview
  88. 8.15.3 Chiesi Pharmaceuticals Alpha-1 Lung Disease Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Chiesi Pharmaceuticals Alpha-1 Lung Disease Product Portfolio
  90. 8.15.5 Chiesi Pharmaceuticals Recent Developments
  91. 8.16 Boehringer Ingelheim
  92. 8.16.1 Boehringer Ingelheim Company Information
  93. 8.16.2 Boehringer Ingelheim Business Overview
  94. 8.16.3 Boehringer Ingelheim Alpha-1 Lung Disease Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Boehringer Ingelheim Alpha-1 Lung Disease Product Portfolio
  96. 8.16.5 Boehringer Ingelheim Recent Developments
  97. 8.17 Biogen
  98. 8.17.1 Biogen Company Information
  99. 8.17.2 Biogen Business Overview
  100. 8.17.3 Biogen Alpha-1 Lung Disease Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Biogen Alpha-1 Lung Disease Product Portfolio
  102. 8.17.5 Biogen Recent Developments
  103. 8.18 Baxalta
  104. 8.18.1 Baxalta Company Information
  105. 8.18.2 Baxalta Business Overview
  106. 8.18.3 Baxalta Alpha-1 Lung Disease Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Baxalta Alpha-1 Lung Disease Product Portfolio
  108. 8.18.5 Baxalta Recent Developments
  109. 8.19 Arrowhead Research Corporation
  110. 8.19.1 Arrowhead Research Corporation Company Information
  111. 8.19.2 Arrowhead Research Corporation Business Overview
  112. 8.19.3 Arrowhead Research Corporation Alpha-1 Lung Disease Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Arrowhead Research Corporation Alpha-1 Lung Disease Product Portfolio
  114. 8.19.5 Arrowhead Research Corporation Recent Developments
  115. 8.20 Abeona Therapeutics
  116. 8.20.1 Abeona Therapeutics Company Information
  117. 8.20.2 Abeona Therapeutics Business Overview
  118. 8.20.3 Abeona Therapeutics Alpha-1 Lung Disease Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Abeona Therapeutics Alpha-1 Lung Disease Product Portfolio
  120. 8.20.5 Abeona Therapeutics Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst